Granules India
Granules India Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Controlled substances and ADHD medications, including lisdexamfetamine, show strong growth potential with filings in multiple countries beyond the US (EU and ROW expected from FY '29 for finished doses, APIs earlier). Granules India aims for sustained PAT positive performance on an annual basis from FY '27, despite inherent quarter-to-quarter variations in the project-driven CDMO business.
From Granules India's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Controlled substances and ADHD medications, including lisdexamfetamine, show strong growth potential with filings in multiple countries beyond the US (EU and ROW expected from FY '29 for finished doses, APIs earlier).
- Focus on complex product filings, especially in controlled substances and oncology, with first-to-file and NCE-1 targeted launches planned, supporting day-one market entry.
- CDMO business, including peptides and chemicals (Ascelis), aims for sustainable profitability from FY '27, with active projects advancing to commercial supply.
- Senn Chemicals identified as a key growth pillar, expected to contribute significantly over 3-4 years.
- New API launches and integrated formulations continue to drive API segment growth.
- Capex (~INR600 crores) will support broad-based expansion, including new API facility, IT, and US distribution center.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Granules India said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Granules India is undertaking major capex investments including building peptide API capacity at Zurich and a brownfield manufacturing facility for intermediates in India.
- Planning for a new India peptide API facility is underway, expected to commence approximately a year later.
- A commercial DCDA plant in Vizag is planned with an estimated capex of around INR 200 crore, moving from pilot to commercial stage in 2 to 2.5 months.
- FY '27 capex is expected to be broad-based (~INR 600 crore), including a new API facility, IT investments, and a U.S. distribution center/warehouse.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Granules India said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Specific details regarding the current order book for the Senn Chemicals CDMO project are not disclosed by the management.
- Sanjay Kumar stated that they cannot share information related to the order book for the Senn project.
- The CDMO capacity is demand-linked, with capex deployment based on customer program progress and commitments.
- Utilization was healthy in Q4 FY'26, and new capacities coming online in the second half of the year are expected to be quickly utilized.
2 more points management made on order book & pipeline
Granules India — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.5K Cr, net profit ₹202 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Granules India Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Granules India Q4 FY26 results?
Controlled substances and ADHD medications, including lisdexamfetamine, show strong growth potential with filings in multiple countries beyond the US (EU and ROW expected from FY '29 for finished doses, APIs earlier). Granules India aims for sustained PAT positive performance on an annual basis from FY '27, despite inherent quarter-to-quarter variations in the project-driven CDMO business.
What is Granules India share price analysis?
Granules India currently shows a neutral. The stock trades at a P/E of 32.7 with a market cap of ₹21,265 Cr. Investors should review the full earnings analysis for detailed insights.
Is Granules India planning capital expenditure?
Granules India is undertaking major capex investments including building peptide API capacity at Zurich and a brownfield manufacturing facility for intermediates in India.
Keep Granules India on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.